tiprankstipranks
Trending News
More News >
Aion Therapeutic Inc (TSE:AION)
:AION
Canadian Market

Aion Therapeutic Inc (AION) AI Stock Analysis

Compare
6 Followers

Top Page

TS

Aion Therapeutic Inc

(AION)

Rating:31Underperform
Price Target:
Aion Therapeutic Inc's stock score reflects significant financial weaknesses, including operational losses and high leverage, which weigh heavily on the assessment. The technical analysis indicates a bearish trend, while valuation is challenging due to negative earnings and lack of dividend yield. The company's revenue growth is a positive factor, but substantial improvements are necessary for a more favorable outlook.

Aion Therapeutic Inc (AION) vs. iShares MSCI Canada ETF (EWC)

Aion Therapeutic Inc Business Overview & Revenue Model

Company DescriptionAion Therapeutic Inc (AION) is a biotechnology company focused on the research and development of therapeutic interventions for various health conditions. The company operates in the pharmaceutical and biotechnology sectors, specializing in developing treatments that leverage cannabis, mushrooms, and other natural compounds. Aion Therapeutic aims to create innovative healthcare solutions through its core products and services in the medical and wellness industries.
How the Company Makes MoneyAion Therapeutic Inc generates revenue primarily through the development and commercialization of its proprietary therapeutic products. These products are designed to address a range of health conditions using natural compounds. The company's revenue model includes licensing agreements, product sales, and potential partnerships with larger pharmaceutical firms for distribution and co-development opportunities. Aion's earnings are also influenced by its ongoing research and development efforts, which aim to expand its product pipeline and enhance its market presence in the biotechnology sector. Significant partnerships with research institutions and healthcare providers may also contribute to its revenue streams.

Aion Therapeutic Inc Financial Statement Overview

Summary
Aion Therapeutic Inc faces several financial challenges, including significant operational losses, high leverage, and negative equity, which collectively indicate a precarious financial position. Revenue growth is a positive sign, but substantial improvements in profitability and balance sheet health are needed to strengthen the company's financial standing.
Income Statement
25
Negative
Aion Therapeutic Inc has shown a significant increase in revenue over the past year, moving from no revenue to $1.47 million in TTM (Trailing-Twelve-Months). However, the company continues to face challenges with negative EBIT and EBITDA margins, both of which indicate operational inefficiencies. The net profit margin is also deeply negative at -451.1%, reflecting substantial losses relative to revenue.
Balance Sheet
20
Very Negative
The company has a negative stockholders' equity, indicating a weak balance sheet with liabilities exceeding assets. Debt levels are high, with a negative equity ratio, showcasing financial instability. The debt-to-equity ratio is not meaningful due to negative equity, but the overall financial leverage is concerning.
Cash Flow
30
Negative
Aion Therapeutic Inc's cash flows are under pressure with negative free cash flow and operating cash flow. There's a significant reliance on financing activities to support operations. The operating cash flow to net income ratio is negative, indicating challenges in converting income into cash.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue1.47M367.48K0.000.000.000.00
Gross Profit298.90K163.12K-17.30K-65.29K-111.05K
EBITDA-6.19M-6.07M-89.52K-3.68M-7.95M-240.59K
Net Income-6.65M-6.29M-256.66K-3.82M-8.27M-672.83K
Balance Sheet
Total Assets1.21M702.86K210.67K150.14K1.60M3.34M
Cash, Cash Equivalents and Short-Term Investments13.82K68.34K336.00239.83K239.83K612.79K
Total Debt2.81M2.08M826.47K744.06K566.53K958.91K
Total Liabilities5.88M4.57M2.94M2.56M1.21M1.20M
Stockholders Equity-4.67M-3.87M-2.73M-2.41M397.46K2.13M
Cash Flow
Free Cash Flow-1.55M-845.04K-41.40K-2.79M-3.58M-756.38K
Operating Cash Flow-1.55M-845.04K-41.40K-1.35M-2.13M-551.75K
Investing Cash Flow0.00-289.42K135.19K-1.38M-1.38M-333.19K
Financing Cash Flow1.41M1.12M163.25K1.20M3.00M-125.00K

Aion Therapeutic Inc Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.01
Negative
200DMA
0.01
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
49.24
Neutral
STOCH
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AION, the sentiment is Neutral. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 49.24 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:AION.

Aion Therapeutic Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
TSNEO
71
Outperform
C$640.33M-3.70%2.61%-12.01%-698.83%
54
Neutral
C$1.03B-25.08%-0.11%11.22%
46
Neutral
C$200.35M-3.25-23.22%2.71%21.07%-1.26%
37
Underperform
$1.97M-42.90%51.37%
31
Underperform
C$4.84M
563.34%-68.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:AION
Aion Therapeutic Inc
0.01
0.00
0.00%
TSE:CURA
Curaleaf Holdings
1.65
-4.02
-70.90%
TSE:CYBN
Cybin
0.14
0.00
0.00%
TSE:NEO
Neo Performance Materials Inc
15.90
7.98
100.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025